Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders (2013 - 2026)

Armata Pharmaceuticals has disclosed Net Income towards Common Stockholders across 14 years of filings, most recently posting -$115.3 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$115.3 million, down 883.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$162.4 million (down 208.53% YoY), and the FY2025 annual result was -$53.2 million, changed 0.09% from the prior year.
• Net Income towards Common Stockholders came in at -$115.3 million for Q1 2026 at Armata Pharmaceuticals, down from -$18.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$8.6 million in Q3 2022 to a low of -$115.3 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$11.7 million (2025), against an average of -$18.8 million.
• Across the five-year window, Net Income towards Common Stockholders surged 53.1% in 2025 and tumbled 883.01% in 2026, its largest moves.
• Armata Pharmaceuticals' Net Income towards Common Stockholders stood at -$10.3 million in 2022, then dropped by 6.27% to -$11.0 million in 2023, then declined by 26.07% to -$13.8 million in 2024, then plunged by 35.01% to -$18.7 million in 2025, then slumped by 518.25% to -$115.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$115.3 million (Q1 2026), -$18.7 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.